Linden Advisors’s CERo Therapeutics Warrants CEROW Stock Holding History

Linden Advisors’s Portfolio CEROW Stock Details CEROW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-249,999	Closed	-$3.6K	–	489
2025 Q3	$3.6K	Hold	249,999	–	–	﹤0.01%	405
2025 Q2	$5.72K	Hold	249,999	–	–	﹤0.01%	372
2025 Q1	$3.33K	Hold	249,999	–	–	﹤0.01%	303
2024 Q4	$2.3K	Hold	249,999	–	–	﹤0.01%	261
2024 Q3	$1.48K	Hold	249,999	–	–	﹤0.01%	276
2024 Q2	$5.63K	Hold	249,999	–	–	﹤0.01%	278
2024 Q1	$20K	Hold	249,999	–	–	﹤0.01%	265
2023 Q4	$6.88K	Hold	249,999	–	–	﹤0.01%	302
2023 Q3	$19.2K	Hold	249,999	–	–	﹤0.01%	305
2023 Q2	$16.4K	Hold	249,999	–	–	﹤0.01%	331
2023 Q1	$10K	Hold	249,999	–	–	﹤0.01%	431
2022 Q4	$12.6K	Hold	249,999	–	–	﹤0.01%	487
2022 Q3	$27K	Hold	249,999	–	–	﹤0.01%	570
2022 Q2	$27K	Hold	249,999	–	–	﹤0.01%	637
2022 Q1	$55K	Buy	+249,999	New	+$92.8K	﹤0.01%	650

Other funds holding CEROW

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Linden Advisors's CEROW Position: Q4 2025 in Review

Linden Advisors sold out of CERo Therapeutics Warrants (CEROW) in Q4 2025, closing a stake of 249,999 shares — an estimated $3.6K sold.

Linden Advisors first reported a position in CEROW in Q1 2022 and held it in 15 quarters. The position peaked at $55K in Q1 2022. 1 fund tracked by Wall St. Rank holds CEROW as of Q4 2025.

Linden Advisors reported no remaining CERo Therapeutics Warrants position as of Q4 2025 after selling out during the quarter.
Linden Advisors sold 249,999 CERo Therapeutics Warrants shares in Q4 2025, an estimated $3.6K.
Linden Advisors first reported a position in CERo Therapeutics Warrants in Q1 2022 and held it in 15 quarters.
Linden Advisors's CERo Therapeutics Warrants position peaked at $55K in Q1 2022.
1 fund tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q4 2025.

Based on Linden Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.